Quality of Life as an Outcome and a Mediator of Other Outcomes in Patients with Schizophrenia

  • Anne KarowEmail author
  • Monika Bullinger
  • Martin Lambert


During the past decades subjective quality of life (hereafter QOL) has been proven to be a valid and useful outcome criterion in patients with schizophrenia besides the assessment of clinical parameters such as symptoms or daily functioning. Important predictors for a favorable outcome in patients with schizophrenia are a shorter duration of untreated psychosis, better premorbid functioning, an early treatment response, a lower level of psychopathology or illness severity, and better daily and social functioning at beginning of treatment (Lambert et al. 2010a). Clinical outcome is further compromised by a high risk of medication nonadherence and service disengagement (Velligan et al. 2009) and of comorbid disorders, especially substance use (Fleischhacker et al. 2008). All these factors directly or indirectly mediate QOL in patients with schizophrenia.


Social Anxiety Negative Symptom Assertive Community Treatment Antipsychotic Treatment Symptomatic Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11:95–106.PubMedCrossRefGoogle Scholar
  2. Acta. Brighton; 2001–2012.
  3. Addington DE, McKenzie E, Wang J. Validity of hospital admission as an outcome measure of services for first-episode psychosis. Psychiatr Serv (Washington, DC). 2012;63:280–2.CrossRefGoogle Scholar
  4. AlAqeel B, Margolese HC. Remission in schizophrenia: critical and systematic review. Harv Rev Psychiatry. 2012;20:281–97.PubMedCrossRefGoogle Scholar
  5. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009;12:536–43.PubMedCrossRefGoogle Scholar
  6. Amador XF, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873–9.PubMedCrossRefGoogle Scholar
  7. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51:826–36.PubMedCrossRefGoogle Scholar
  8. Andreasen NC, Carpenter Jr WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–9.PubMedCrossRefGoogle Scholar
  9. Awad AG, Voruganti LN. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2012;30:183–95.PubMedCrossRefGoogle Scholar
  10. Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27:625–36.PubMedCrossRefGoogle Scholar
  11. Barnes TR, Drake RJ, Dunn G, et al. Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. Br J Psychiatry. 2013;203:215–20.PubMedCrossRefGoogle Scholar
  12. Bechdolf A, Pukrop R, Kohn D, et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res. 2005;79:137–43.PubMedCrossRefGoogle Scholar
  13. Bobes J, Ciudad A, Alvarez E, et al. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009;115:58–66.PubMedCrossRefGoogle Scholar
  14. Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107:232–7.PubMedCrossRefGoogle Scholar
  15. Bora E, Sehitoglu G, Aslier M, Atabay I, Veznedaroglu B. Theory of mind and unawareness of illness in schizophrenia: is poor insight a mentalizing deficit? Eur Arch Psychiatry Clin Neurosci. 2007;257:104–11.PubMedCrossRefGoogle Scholar
  16. Boyer L, Aghababian V, Richieri R, et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:271–6.PubMedCrossRefGoogle Scholar
  17. Boyer L, Lancon C, Baumstarck K, et al. Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial. Br J Psychiatry. 2013;202:447–53.PubMedCrossRefGoogle Scholar
  18. Briand C, Vasiliadis HM, Lesage A, et al. Including integrated psychological treatment as part of standard medical therapy for patients with schizophrenia: clinical outcomes. J Nerv Ment Dis. 2006;194:463–70.PubMedCrossRefGoogle Scholar
  19. Brissos S, Dias VV, Balanza-Martinez V, Carita AI, Figueira ML. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res. 2011;129:133–6.PubMedCrossRefGoogle Scholar
  20. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:5372.CrossRefGoogle Scholar
  21. Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophr Res Treatment. 2012;2012:576369.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Carroll A, Fattah S, Clyde Z, et al. Correlates of insight and insight change in schizophrenia. Schizophr Res. 1999;35:247–53.PubMedCrossRefGoogle Scholar
  23. Chang LR, Lin YH, Kuo TB, et al. Autonomic modulation and health-related quality of life among schizophrenic patients treated with non-intensive case management. PLoS One. 2013;6:e26378.CrossRefGoogle Scholar
  24. Chen EY, Tang JY, Hui CL, et al. Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Early Interv Psychiatry. 2011;5:315–23.PubMedCrossRefGoogle Scholar
  25. Chou KR, Shih YW, Chang C, et al. Psychosocial rehabilitation activities, empowerment, and quality of community-based life for people with schizophrenia. Arch Psychiatr Nurs. 2012;26:285–94.PubMedCrossRefGoogle Scholar
  26. Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17:567–76.PubMedCrossRefGoogle Scholar
  27. Cohen CI, Pathak R, Ramirez PM, Vahia I. Outcome among community dwelling older adults with schizophrenia: results using five conceptual models. Community Ment Health J. 2009;45:151–6.PubMedCrossRefGoogle Scholar
  28. Cohen CI, Hassamal SK, Begum N. General coping strategies and their impact on quality of life in older adults with schizophrenia. Schizophr Res. 2011;127:223–8.PubMedCrossRefGoogle Scholar
  29. Cooke MA, Peters ER, Kuipers E, Kumari V. Disease, deficit or denial? Models of poor insight in psychosis. Acta Psychiatr Scand. 2005;112:4–17.PubMedCrossRefGoogle Scholar
  30. Dan A, Kumar S, Avasthi A, Grover S. A comparative study on quality of life of patients of schizophrenia with and without depression. Psychiatry Res. 2011;189:185–9.PubMedCrossRefGoogle Scholar
  31. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125–8.PubMedCrossRefGoogle Scholar
  32. DeHaan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale [Medico-economic study of Leponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. Psychopharmacology (Berl). 2002;162:24–8.CrossRefGoogle Scholar
  33. Delespaul PH. Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschr Psychiatr. 2013;55:427–38.PubMedGoogle Scholar
  34. Dickerson FB, Boronow JJ, Ringel N, Parente F. Lack of insight among outpatients with schizophrenia. Psychiatr Serv (Washington, DC). 1997;48:195–9.CrossRefGoogle Scholar
  35. Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol. 2007;22:51–5.PubMedGoogle Scholar
  36. Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res. 2003;62:165–73.PubMedCrossRefGoogle Scholar
  37. Drake RJ, Pickles A, Bentall RP, et al. The evolution of insight, paranoia and depression during early schizophrenia. Psychol Med. 2004;34:285–92.PubMedCrossRefGoogle Scholar
  38. Eack S, Newhill C. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225–37.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014a;68:416–27.PubMedCrossRefGoogle Scholar
  40. Einarson TR, Pudas H, Goswami P, van Impe K, Bereza BG. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ. 2014b,68:1–29.Google Scholar
  41. Eklund M. Work status, daily activities and quality of life among people with severe mental illness. Qual Life Res. 2009;18:163–70.PubMedCrossRefGoogle Scholar
  42. Faerden A, Nesvag R, Marder SR. Definitions of the term ‘recovered’ in schizophrenia and other disorders. Psychopathology. 2008;41:271–8.PubMedCrossRefGoogle Scholar
  43. (FDA) USFaDA. Patient-reported outcome measures: use in medical product development to support labelling claims. In: Guidance for industry. FDA, US Government. 2006.Google Scholar
  44. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69:514–9.PubMedCrossRefGoogle Scholar
  45. Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012a;197:199–205.PubMedCrossRefGoogle Scholar
  46. Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One. 2012b;7:e37087.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L. Schizophrenia and quality of life: how important are symptoms and functioning? Int J Ment Heal Syst. 2010;4:31.CrossRefGoogle Scholar
  48. Gilleen J, David AS. The cognitive neuropsychiatry of delusions: from psychopathology to neuropsychology and back again. Psychol Med. 2005;35:5–12.PubMedCrossRefGoogle Scholar
  49. Goldberg RW, Green-Paden LD, Lehman AF, Gold JM. Correlates of insight in serious mental illness. J Nerv Ment Dis. 2001;189:137–45.PubMedCrossRefGoogle Scholar
  50. Green C, Garety PA, Freeman D, et al. Content and affect in persecutory delusions. Br J Clin Psychol Br Psychol Soc. 2006;45:561–77.CrossRefGoogle Scholar
  51. Haro JM, Novick D, Perrin E, Bertsch J, Knapp M. Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship? Psychiatry Res. 2014;220:163–9.PubMedCrossRefGoogle Scholar
  52. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35:300–6.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Harvey PD, Pappadopulos E, Lombardo I, Kremer CM. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. Schizophr Res. 2009;115:24–9.PubMedCrossRefGoogle Scholar
  54. Harvey PD, Sabbag S, Prestia D, et al. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res. 2012;46:1546–52.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M. Insight into psychosis and quality of life. Compr Psychiatry. 2006;47:265–9.PubMedCrossRefGoogle Scholar
  56. Hayhurst KP, Drake RJ, Massie JA, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2013;29:191–6.PubMedCrossRefGoogle Scholar
  57. Haynes VS, Zhu B, Stauffer VL, et al. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry. 2012;12:222.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–98.PubMedCrossRefGoogle Scholar
  59. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93:160–8.PubMedCrossRefGoogle Scholar
  60. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932–9.PubMedCrossRefGoogle Scholar
  61. Hofer A, Rettenbacher MA, Widschwendter CG, et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256(4):246–55.PubMedCrossRefGoogle Scholar
  62. Hofer A, Rettenbacher MA, Edlinger M, et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry. 2007;40:1–8.PubMedCrossRefGoogle Scholar
  63. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171–80.PubMedCrossRefGoogle Scholar
  64. Iqbal Z, Birchwood M, Chadwick P, Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 2. Testing the validity of a social ranking model. Br J Psychiatry. 2000;177:522–8.PubMedCrossRefGoogle Scholar
  65. Jaaskelainen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39:1296–306.PubMedCrossRefGoogle Scholar
  66. Jaaskelainen E, Haapea M, Rautio N, et al. Twenty years of schizophrenia research in the Northern Finland Birth Cohort 1966: a systematic review. Schizophr Res Treatment. 2015;2015:524875.PubMedPubMedCentralCrossRefGoogle Scholar
  67. Karadayi G, Emiroglu B, Ucok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychiatry. 2012;52:701–7.CrossRefGoogle Scholar
  68. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38:320–6.PubMedCrossRefGoogle Scholar
  69. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75–80.PubMedCrossRefGoogle Scholar
  70. Karow A, Pajonk FG, Reimer J, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2008;258:152–9.PubMedCrossRefGoogle Scholar
  71. Karow A, Moritz S, Lambert M, Schottle D, Naber D. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012a;27:401–5.PubMedCrossRefGoogle Scholar
  72. Karow A, Naber D, Lambert M, Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry. 2012b;27(6):426–31.PubMedCrossRefGoogle Scholar
  73. Karow A, Reimer J, Konig HH, et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012c;73:e402–8.PubMedCrossRefGoogle Scholar
  74. Karow A, Wittmann L, Schottle D, Schafer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2015;16:185–95.Google Scholar
  75. Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res. 2003;60:71–80.PubMedCrossRefGoogle Scholar
  76. Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. In: Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrchet/Boston: Kluwer; 2003.Google Scholar
  77. Koren D, Seidman LJ, Poyurovsky M, et al. The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study. Schizophr Res. 2004;70:195–202.PubMedCrossRefGoogle Scholar
  78. Kumazaki H, Kobayashi H, Niimura H, et al. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study. Compr Psychiatry. 2012;53:946–51.PubMedCrossRefGoogle Scholar
  79. Kurtz MM, Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship? Schizophr Res. 2010;127:157–62.CrossRefGoogle Scholar
  80. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690–7.PubMedCrossRefGoogle Scholar
  81. Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007;115:106–13.PubMedCrossRefGoogle Scholar
  82. Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220–9.PubMedCrossRefGoogle Scholar
  83. Lambert M, Schimmelmann BG, Naber D, et al. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277–83.PubMedCrossRefGoogle Scholar
  84. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010a;12:393–407.PubMedPubMedCentralGoogle Scholar
  85. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010b;25(4):220–9.PubMedCrossRefGoogle Scholar
  86. Lambert M, Bock T, Schottle D, et al. Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2010c;71(10):1313–23.PubMedCrossRefGoogle Scholar
  87. Landolt K, Rossler W, Burns T, et al. The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2012a;262:207–16.PubMedCrossRefGoogle Scholar
  88. Landolt K, Rossler W, Burns T, et al. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med. 2012b;42:1461–73.PubMedCrossRefGoogle Scholar
  89. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Winchester, England). 2006;10:iii–iv, ix–xi, 1–165.Google Scholar
  90. Liraud F, Droulout T, Parrot M, Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J Nerv Ment Dis. 2004;192:352–6.PubMedCrossRefGoogle Scholar
  91. Maat A, Fett AK, Derks E. Social cognition and quality of life in schizophrenia. Schizophr Res. 2012;137:212–8.PubMedCrossRefGoogle Scholar
  92. Marchinko S, Clarke D. The Wellness Planner: empowerment, quality of life, and continuity of care in mental illness. Arch Psychiatr Nurs. 2011;25:284–93.PubMedCrossRefGoogle Scholar
  93. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev Online. 2011;(4):CD001089.Google Scholar
  94. Maurino J, Sanjuan J, Haro JM, Diez T, Ballesteros J. Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence. 2011;5:471–4.PubMedPubMedCentralCrossRefGoogle Scholar
  95. McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis. 1989;177:43–7.PubMedCrossRefGoogle Scholar
  96. Meesters PD, Comijs HC, de Haan L, et al. Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res. 2011;147:275–80.CrossRefGoogle Scholar
  97. Meijer CJ, Koeter MW, Sprangers MA, Schene AH. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2009;44:361–8.PubMedCrossRefGoogle Scholar
  98. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36:1349–62.PubMedCrossRefGoogle Scholar
  99. Mintz AR, Addington J, Addington D. Insight in early psychosis: a 1-year follow-up. Schizophr Res. 2004;67:213–7.PubMedCrossRefGoogle Scholar
  100. Moritz S, Werner R, von Collani G. The inferiority complex in paranoia re-addressed. A study with the Implicit Association Test. Cogn Neuropsychiatry. 2006;11:402–15.PubMedCrossRefGoogle Scholar
  101. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10 Suppl 3:133–8.PubMedGoogle Scholar
  102. Naber D, Kollack-Walker S, Chen J, et al. Predicting a ‘combined treatment outcome’ in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being. Pharmacopsychiatry. 2013;46:114–9.PubMedCrossRefGoogle Scholar
  103. Nordentoft M, Ohlenschlaeger J, Thorup A, et al. Deinstitutionalization revisited: a 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. Psychol Med. 2010;40:1619–26.PubMedCrossRefGoogle Scholar
  104. Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37 Suppl 2:S33–40.PubMedPubMedCentralCrossRefGoogle Scholar
  105. O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–70.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Ojeda N, Sanchez P, Pena J, et al. An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms. Actas Esp Psiquiatr. 2012;40:10–8.PubMedGoogle Scholar
  107. Pedrelli P, McQuaid JR, Granholm E, et al. Measuring cognitive insight in middle-aged and older patients with psychotic disorders. Schizophr Res. 2004;71:297–305.PubMedCrossRefGoogle Scholar
  108. Penn DL, Uzenoff SR, Perkins D, et al. A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis. Schizophr Res. 2011;125:247–56.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Peuskens J, Gorwood P. How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur Psychiatry. 2012;27:391–5.PubMedCrossRefGoogle Scholar
  110. Pitkanen A, Valimaki M, Kuosmanen L, et al. Patient education methods to support quality of life and functional ability among patients with schizophrenia: a randomised clinical trial. Qual Life Res. 2012;21:247–56.PubMedCrossRefGoogle Scholar
  111. Priebe S, McCabe R, Junghan U, et al. Association between symptoms and quality of life in patients with schizophrenia: a pooled analysis of changes over time. Schizophr Res. 2011;133:17–21.PubMedCrossRefGoogle Scholar
  112. Putzhammer A, Perfahl M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry. 2005;38:132–8.PubMedCrossRefGoogle Scholar
  113. Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147–50.PubMedCrossRefGoogle Scholar
  114. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150:339–42.PubMedCrossRefGoogle Scholar
  115. Rajagopalan K, Hassan M, O’Day K, Meyer K, Grossman F. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. J Med Econ. 2013;16:951–61.PubMedCrossRefGoogle Scholar
  116. Reichenberg A, Caspi A, Harrington H, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry. 2010;167:160–9.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Renwick L, Jackson D, Foley S, et al. Depression and quality of life in first-episode psychosis. Compr Psychiatry. 2012;53:451–5.PubMedCrossRefGoogle Scholar
  118. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis. 2003;191:287–94.PubMedGoogle Scholar
  119. Ritsner MS, Grinshpoon A. Ten-year quality of life outcomes of patients with schizophrenia and schizoaffective disorders. Clin Schizophr Relat Psychoses. 2015, Fall issue, 125–134.Google Scholar
  120. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14:1693–703.PubMedCrossRefGoogle Scholar
  121. Ritsner MS, Lisker A, Arbitman M. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2014;21:837–47.CrossRefGoogle Scholar
  122. Rocca P, Giugiario M, Montemagni C, et al. Quality of life and psychopathology during the course of schizophrenia. Compr Psychiatry. 2009;50:542–8.PubMedCrossRefGoogle Scholar
  123. Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.PubMedCrossRefGoogle Scholar
  124. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry. 2000;177:149–55.PubMedCrossRefGoogle Scholar
  125. Sanz M, Constable G, Lopez-Ibor I, Kemp R, David AS. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med. 1998;28:437–46.PubMedCrossRefGoogle Scholar
  126. Schennach-Wolff R, Jager M, Seemuller F, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009;113:210–7.PubMedCrossRefGoogle Scholar
  127. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol. 2005;15:249–58.PubMedCrossRefGoogle Scholar
  128. Schöttle D, Karow A, Schimmelmann BG, Lambert M. Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry. 2013;26:384–408.PubMedCrossRefGoogle Scholar
  129. Schroeder K, Huber CG, Jelinek L, Moritz S. Subjective well-being, but not subjective mental functioning shows positive associations with neuropsychological performance in schizophrenia-spectrum disorders. Compr Psychiatry. 2012;54:824–30.CrossRefGoogle Scholar
  130. Schwartz RC. Insight and illness in chronic schizophrenia. Compr Psychiatry. 1998;39:249–54.PubMedCrossRefGoogle Scholar
  131. Schwartz RC, Smith SD. Suicidality and psychosis: the predictive potential of symptomatology and insight into illness. J Psychiatr Res. 2004;38:185–91.PubMedCrossRefGoogle Scholar
  132. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res. 2004;129:141–7.PubMedCrossRefGoogle Scholar
  133. Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004;38:169–76.PubMedCrossRefGoogle Scholar
  134. Stein LI, Santos AB. Assertive community treatment of persons with severe mental illness. New York: W. W. Norton & Company, Inc; 2000.Google Scholar
  135. Subotnik KL, Nuechterlein KH, Irzhevsky V, et al. Is unawareness of psychotic disorder a neurocognitive or psychological defensiveness problem? Schizophr Res. 2005;75:147–57.PubMedCrossRefGoogle Scholar
  136. Sugawara N, Yasui-Furukori N, Sato Y, et al. Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry. 2013;13:108.PubMedPubMedCentralCrossRefGoogle Scholar
  137. Switaj P, Wciorka J, Smolarska-Switaj J, Grygiel P. Extent and predictors of stigma experienced by patients with schizophrenia. Eur Psychiatry. 2009;24:513–20.PubMedCrossRefGoogle Scholar
  138. Tang IC, Wu HC. Quality of life and self-stigma in individuals with schizophrenia. Psychiatry Q. 2012;83:497–507.CrossRefGoogle Scholar
  139. Teague GB, Mueser KT, Rapp CA. Advances in fidelity measurement for mental health services research: four measures. Psychiatr Serv (Washington, DC). 2012;63:765–71.CrossRefGoogle Scholar
  140. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304–15.PubMedCrossRefGoogle Scholar
  141. Ucok A, Karadayi G, Emiroglu B, Sartorius N. Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. Psychiatry Res. 2013;209:333–9.PubMedCrossRefGoogle Scholar
  142. Urbach M, Brunet-Gouet E, Bazin N, Hardy-Bayle MC, Passerieux C. Correlations of theory of mind deficits with clinical patterns and quality of life in schizophrenia. Front Psychiatry. 2013;4:30.PubMedPubMedCentralCrossRefGoogle Scholar
  143. van Baars AW, Wierdsma AI, Hengeveld MW, Mulder CL. Improved insight affects social outcomes in involuntarily committed psychotic patients: a longitudinal study in the Netherlands. Compr Psychiatry. 2013;54:873–9.PubMedCrossRefGoogle Scholar
  144. Vancampfort D, Vansteelandt K, Scheewe T, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012a;126:12–20.PubMedCrossRefGoogle Scholar
  145. Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012b;125:352–62.PubMedCrossRefGoogle Scholar
  146. Vatne S, Bjorkly S. Empirical evidence for using subjective quality of life as an outcome variable in clinical studies A meta-analysis of correlates and predictors in persons with a major mental disorder living in the community. Clin Psychol Rev. 2008;28:869–89.PubMedCrossRefGoogle Scholar
  147. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1–46; quiz 47–8.PubMedGoogle Scholar
  148. Ware J. SF-36 health survey. Manual and interpretation guide. Boston: Health Institute, New England Medical Center; 1993.Google Scholar
  149. Whitty P, Browne S, Clarke M, et al. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. J Nerv Ment Dis. 2004;192:805–9.PubMedCrossRefGoogle Scholar
  150. WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28:551–8.CrossRefGoogle Scholar
  151. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull. 2007;33:792–6.PubMedCrossRefGoogle Scholar
  152. Yeh CB, Huang YS, Tang CS, et al. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nord J Psychiatry. 2013;68:219–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Psychiatry and Psychotherapy & Department of Child and Adolescent Psychiatry, Centre for Psychosocial MedicineUniversity Medical Centre Hamburg-EppendorfHamburgGermany
  2. 2.Institute for Medical Psychology, Centre for Psychosocial MedicineUniversity Medical Centre Hamburg-EppendorfHamburgGermany

Personalised recommendations